INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2270503, encodeId=f8b522e0503f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：淀粉;纤维素 经验分享：提交一周送审，两周初审结束, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b54c9485214, createdName=ms1000000879411280, createdTime=Mon Jun 23 10:09:45 CST 2025, time=2025-06-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2141072, encodeId=008d21410e2f0, content=10号投稿，当天with editor。15号变成decision，现在还在等待决定。已经快一个月了，有相同经历的朋友吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bb75418039, createdName=gyoun9, createdTime=Tue Jun 06 14:51:37 CST 2023, time=2023-06-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2248748, encodeId=160e2248e48f8, content=一审14个月，一直跟我说审稿人还缺一个，我到底要不要撤稿，耽误太久太久了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c375142848, createdName=1467d47dm55暂无昵称, createdTime=Sun Jan 19 07:34:14 CST 2025, time=2025-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2162463, encodeId=8ce221624639f, content=投稿7个月了，外审时间都半年了，催了几次回复都一样。问一下大家，是不是审稿人不回复，编辑就一直等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rRiaicFp2D5Zialtibib5bH8Xicoiaa0UkU4YtcrrAfpFuwiaAlBPjztFLu3icxdzV1zkf1wYjZRbfdCsLEUtic5XuGWY1HQ/132, createdBy=b6f92385679, createdName=superzera, createdTime=Thu Oct 12 21:40:23 CST 2023, time=2023-10-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2239073, encodeId=e6a722390e3ed, content=9月28号Under Review，11月25日还在找审稿人，整整两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Mon Nov 25 15:38:06 CST 2024, time=2024-11-25, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2238647, encodeId=67a7223864e06, content=审稿速度:6.0 经验分享：二审2个月，找了第3个审稿人，审的最初投稿版本，用前两个审稿人的问题给我拒了，去哪说理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6a8350383, createdName=ms6000001780597345, createdTime=Sat Nov 23 12:21:10 CST 2024, time=2024-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省)]

2025-06-23 ms1000000879411280 来自江苏省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：淀粉;纤维素
经验分享：提交一周送审，两周初审结束

12 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2270503, encodeId=f8b522e0503f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：淀粉;纤维素 经验分享：提交一周送审，两周初审结束, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b54c9485214, createdName=ms1000000879411280, createdTime=Mon Jun 23 10:09:45 CST 2025, time=2025-06-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2141072, encodeId=008d21410e2f0, content=10号投稿，当天with editor。15号变成decision，现在还在等待决定。已经快一个月了，有相同经历的朋友吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bb75418039, createdName=gyoun9, createdTime=Tue Jun 06 14:51:37 CST 2023, time=2023-06-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2248748, encodeId=160e2248e48f8, content=一审14个月，一直跟我说审稿人还缺一个，我到底要不要撤稿，耽误太久太久了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c375142848, createdName=1467d47dm55暂无昵称, createdTime=Sun Jan 19 07:34:14 CST 2025, time=2025-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2162463, encodeId=8ce221624639f, content=投稿7个月了，外审时间都半年了，催了几次回复都一样。问一下大家，是不是审稿人不回复，编辑就一直等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rRiaicFp2D5Zialtibib5bH8Xicoiaa0UkU4YtcrrAfpFuwiaAlBPjztFLu3icxdzV1zkf1wYjZRbfdCsLEUtic5XuGWY1HQ/132, createdBy=b6f92385679, createdName=superzera, createdTime=Thu Oct 12 21:40:23 CST 2023, time=2023-10-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2239073, encodeId=e6a722390e3ed, content=9月28号Under Review，11月25日还在找审稿人，整整两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Mon Nov 25 15:38:06 CST 2024, time=2024-11-25, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2238647, encodeId=67a7223864e06, content=审稿速度:6.0 经验分享：二审2个月，找了第3个审稿人，审的最初投稿版本，用前两个审稿人的问题给我拒了，去哪说理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6a8350383, createdName=ms6000001780597345, createdTime=Sat Nov 23 12:21:10 CST 2024, time=2024-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省)]

2023-09-20 lovebanana 来自江苏省

偏重的研究方向：肿瘤;药物化学
经验分享：有没有是cancer letter让转投过来的？机会大不大？

133 12 举报

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2270503, encodeId=f8b522e0503f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：淀粉;纤维素 经验分享：提交一周送审，两周初审结束, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b54c9485214, createdName=ms1000000879411280, createdTime=Mon Jun 23 10:09:45 CST 2025, time=2025-06-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2141072, encodeId=008d21410e2f0, content=10号投稿，当天with editor。15号变成decision，现在还在等待决定。已经快一个月了，有相同经历的朋友吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bb75418039, createdName=gyoun9, createdTime=Tue Jun 06 14:51:37 CST 2023, time=2023-06-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2248748, encodeId=160e2248e48f8, content=一审14个月，一直跟我说审稿人还缺一个，我到底要不要撤稿，耽误太久太久了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c375142848, createdName=1467d47dm55暂无昵称, createdTime=Sun Jan 19 07:34:14 CST 2025, time=2025-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2162463, encodeId=8ce221624639f, content=投稿7个月了，外审时间都半年了，催了几次回复都一样。问一下大家，是不是审稿人不回复，编辑就一直等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rRiaicFp2D5Zialtibib5bH8Xicoiaa0UkU4YtcrrAfpFuwiaAlBPjztFLu3icxdzV1zkf1wYjZRbfdCsLEUtic5XuGWY1HQ/132, createdBy=b6f92385679, createdName=superzera, createdTime=Thu Oct 12 21:40:23 CST 2023, time=2023-10-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2239073, encodeId=e6a722390e3ed, content=9月28号Under Review，11月25日还在找审稿人，整整两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Mon Nov 25 15:38:06 CST 2024, time=2024-11-25, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2238647, encodeId=67a7223864e06, content=审稿速度:6.0 经验分享：二审2个月，找了第3个审稿人，审的最初投稿版本，用前两个审稿人的问题给我拒了，去哪说理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6a8350383, createdName=ms6000001780597345, createdTime=Sat Nov 23 12:21:10 CST 2024, time=2024-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省)]

2023-06-06 gyoun9 来自北京

10号投稿，当天with editor。15号变成decision，现在还在等待决定。已经快一个月了，有相同经历的朋友吗

158 17 举报

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2270503, encodeId=f8b522e0503f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：淀粉;纤维素 经验分享：提交一周送审，两周初审结束, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b54c9485214, createdName=ms1000000879411280, createdTime=Mon Jun 23 10:09:45 CST 2025, time=2025-06-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2141072, encodeId=008d21410e2f0, content=10号投稿，当天with editor。15号变成decision，现在还在等待决定。已经快一个月了，有相同经历的朋友吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bb75418039, createdName=gyoun9, createdTime=Tue Jun 06 14:51:37 CST 2023, time=2023-06-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2248748, encodeId=160e2248e48f8, content=一审14个月，一直跟我说审稿人还缺一个，我到底要不要撤稿，耽误太久太久了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c375142848, createdName=1467d47dm55暂无昵称, createdTime=Sun Jan 19 07:34:14 CST 2025, time=2025-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2162463, encodeId=8ce221624639f, content=投稿7个月了，外审时间都半年了，催了几次回复都一样。问一下大家，是不是审稿人不回复，编辑就一直等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rRiaicFp2D5Zialtibib5bH8Xicoiaa0UkU4YtcrrAfpFuwiaAlBPjztFLu3icxdzV1zkf1wYjZRbfdCsLEUtic5XuGWY1HQ/132, createdBy=b6f92385679, createdName=superzera, createdTime=Thu Oct 12 21:40:23 CST 2023, time=2023-10-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2239073, encodeId=e6a722390e3ed, content=9月28号Under Review，11月25日还在找审稿人，整整两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Mon Nov 25 15:38:06 CST 2024, time=2024-11-25, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2238647, encodeId=67a7223864e06, content=审稿速度:6.0 经验分享：二审2个月，找了第3个审稿人，审的最初投稿版本，用前两个审稿人的问题给我拒了，去哪说理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6a8350383, createdName=ms6000001780597345, createdTime=Sat Nov 23 12:21:10 CST 2024, time=2024-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省)]

2023-09-11 Markxiao 来自香港

偏重的研究方向：分子生物学
经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢

118 7 举报

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2270503, encodeId=f8b522e0503f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：淀粉;纤维素 经验分享：提交一周送审，两周初审结束, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b54c9485214, createdName=ms1000000879411280, createdTime=Mon Jun 23 10:09:45 CST 2025, time=2025-06-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2141072, encodeId=008d21410e2f0, content=10号投稿，当天with editor。15号变成decision，现在还在等待决定。已经快一个月了，有相同经历的朋友吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bb75418039, createdName=gyoun9, createdTime=Tue Jun 06 14:51:37 CST 2023, time=2023-06-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2248748, encodeId=160e2248e48f8, content=一审14个月，一直跟我说审稿人还缺一个，我到底要不要撤稿，耽误太久太久了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c375142848, createdName=1467d47dm55暂无昵称, createdTime=Sun Jan 19 07:34:14 CST 2025, time=2025-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2162463, encodeId=8ce221624639f, content=投稿7个月了，外审时间都半年了，催了几次回复都一样。问一下大家，是不是审稿人不回复，编辑就一直等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rRiaicFp2D5Zialtibib5bH8Xicoiaa0UkU4YtcrrAfpFuwiaAlBPjztFLu3icxdzV1zkf1wYjZRbfdCsLEUtic5XuGWY1HQ/132, createdBy=b6f92385679, createdName=superzera, createdTime=Thu Oct 12 21:40:23 CST 2023, time=2023-10-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2239073, encodeId=e6a722390e3ed, content=9月28号Under Review，11月25日还在找审稿人，整整两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Mon Nov 25 15:38:06 CST 2024, time=2024-11-25, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2238647, encodeId=67a7223864e06, content=审稿速度:6.0 经验分享：二审2个月，找了第3个审稿人，审的最初投稿版本，用前两个审稿人的问题给我拒了，去哪说理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6a8350383, createdName=ms6000001780597345, createdTime=Sat Nov 23 12:21:10 CST 2024, time=2024-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省)]

2025-01-19 1467d47dm55暂无昵称来自江苏省

一审14个月，一直跟我说审稿人还缺一个，我到底要不要撤稿，耽误太久太久了！！

29 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2270503, encodeId=f8b522e0503f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：淀粉;纤维素 经验分享：提交一周送审，两周初审结束, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b54c9485214, createdName=ms1000000879411280, createdTime=Mon Jun 23 10:09:45 CST 2025, time=2025-06-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2141072, encodeId=008d21410e2f0, content=10号投稿，当天with editor。15号变成decision，现在还在等待决定。已经快一个月了，有相同经历的朋友吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bb75418039, createdName=gyoun9, createdTime=Tue Jun 06 14:51:37 CST 2023, time=2023-06-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2248748, encodeId=160e2248e48f8, content=一审14个月，一直跟我说审稿人还缺一个，我到底要不要撤稿，耽误太久太久了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c375142848, createdName=1467d47dm55暂无昵称, createdTime=Sun Jan 19 07:34:14 CST 2025, time=2025-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2162463, encodeId=8ce221624639f, content=投稿7个月了，外审时间都半年了，催了几次回复都一样。问一下大家，是不是审稿人不回复，编辑就一直等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rRiaicFp2D5Zialtibib5bH8Xicoiaa0UkU4YtcrrAfpFuwiaAlBPjztFLu3icxdzV1zkf1wYjZRbfdCsLEUtic5XuGWY1HQ/132, createdBy=b6f92385679, createdName=superzera, createdTime=Thu Oct 12 21:40:23 CST 2023, time=2023-10-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2239073, encodeId=e6a722390e3ed, content=9月28号Under Review，11月25日还在找审稿人，整整两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Mon Nov 25 15:38:06 CST 2024, time=2024-11-25, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2238647, encodeId=67a7223864e06, content=审稿速度:6.0 经验分享：二审2个月，找了第3个审稿人，审的最初投稿版本，用前两个审稿人的问题给我拒了，去哪说理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6a8350383, createdName=ms6000001780597345, createdTime=Sat Nov 23 12:21:10 CST 2024, time=2024-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省)]

2023-10-12 superzera 来自广东省

投稿7个月了，外审时间都半年了，催了几次回复都一样。问一下大家，是不是审稿人不回复，编辑就一直等

113 16 举报

展开16条回复

[GetPortalCommentsPageByObjectIdResponse(id=2270503, encodeId=f8b522e0503f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：淀粉;纤维素 经验分享：提交一周送审，两周初审结束, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b54c9485214, createdName=ms1000000879411280, createdTime=Mon Jun 23 10:09:45 CST 2025, time=2025-06-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2141072, encodeId=008d21410e2f0, content=10号投稿，当天with editor。15号变成decision，现在还在等待决定。已经快一个月了，有相同经历的朋友吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bb75418039, createdName=gyoun9, createdTime=Tue Jun 06 14:51:37 CST 2023, time=2023-06-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2248748, encodeId=160e2248e48f8, content=一审14个月，一直跟我说审稿人还缺一个，我到底要不要撤稿，耽误太久太久了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c375142848, createdName=1467d47dm55暂无昵称, createdTime=Sun Jan 19 07:34:14 CST 2025, time=2025-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2162463, encodeId=8ce221624639f, content=投稿7个月了，外审时间都半年了，催了几次回复都一样。问一下大家，是不是审稿人不回复，编辑就一直等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rRiaicFp2D5Zialtibib5bH8Xicoiaa0UkU4YtcrrAfpFuwiaAlBPjztFLu3icxdzV1zkf1wYjZRbfdCsLEUtic5XuGWY1HQ/132, createdBy=b6f92385679, createdName=superzera, createdTime=Thu Oct 12 21:40:23 CST 2023, time=2023-10-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2239073, encodeId=e6a722390e3ed, content=9月28号Under Review，11月25日还在找审稿人，整整两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Mon Nov 25 15:38:06 CST 2024, time=2024-11-25, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2238647, encodeId=67a7223864e06, content=审稿速度:6.0 经验分享：二审2个月，找了第3个审稿人，审的最初投稿版本，用前两个审稿人的问题给我拒了，去哪说理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6a8350383, createdName=ms6000001780597345, createdTime=Sat Nov 23 12:21:10 CST 2024, time=2024-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省)]

2020-03-29 ms7269483029162029

嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！

142 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2270503, encodeId=f8b522e0503f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：淀粉;纤维素 经验分享：提交一周送审，两周初审结束, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b54c9485214, createdName=ms1000000879411280, createdTime=Mon Jun 23 10:09:45 CST 2025, time=2025-06-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2141072, encodeId=008d21410e2f0, content=10号投稿，当天with editor。15号变成decision，现在还在等待决定。已经快一个月了，有相同经历的朋友吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bb75418039, createdName=gyoun9, createdTime=Tue Jun 06 14:51:37 CST 2023, time=2023-06-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2248748, encodeId=160e2248e48f8, content=一审14个月，一直跟我说审稿人还缺一个，我到底要不要撤稿，耽误太久太久了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c375142848, createdName=1467d47dm55暂无昵称, createdTime=Sun Jan 19 07:34:14 CST 2025, time=2025-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2162463, encodeId=8ce221624639f, content=投稿7个月了，外审时间都半年了，催了几次回复都一样。问一下大家，是不是审稿人不回复，编辑就一直等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rRiaicFp2D5Zialtibib5bH8Xicoiaa0UkU4YtcrrAfpFuwiaAlBPjztFLu3icxdzV1zkf1wYjZRbfdCsLEUtic5XuGWY1HQ/132, createdBy=b6f92385679, createdName=superzera, createdTime=Thu Oct 12 21:40:23 CST 2023, time=2023-10-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2239073, encodeId=e6a722390e3ed, content=9月28号Under Review，11月25日还在找审稿人，整整两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Mon Nov 25 15:38:06 CST 2024, time=2024-11-25, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2238647, encodeId=67a7223864e06, content=审稿速度:6.0 经验分享：二审2个月，找了第3个审稿人，审的最初投稿版本，用前两个审稿人的问题给我拒了，去哪说理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6a8350383, createdName=ms6000001780597345, createdTime=Sat Nov 23 12:21:10 CST 2024, time=2024-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省)]

2024-11-25 ms4255114797740350 来自青海省

9月28号Under Review，11月25日还在找审稿人，整整两个月了

87 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2270503, encodeId=f8b522e0503f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：淀粉;纤维素 经验分享：提交一周送审，两周初审结束, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b54c9485214, createdName=ms1000000879411280, createdTime=Mon Jun 23 10:09:45 CST 2025, time=2025-06-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2141072, encodeId=008d21410e2f0, content=10号投稿，当天with editor。15号变成decision，现在还在等待决定。已经快一个月了，有相同经历的朋友吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bb75418039, createdName=gyoun9, createdTime=Tue Jun 06 14:51:37 CST 2023, time=2023-06-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2248748, encodeId=160e2248e48f8, content=一审14个月，一直跟我说审稿人还缺一个，我到底要不要撤稿，耽误太久太久了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c375142848, createdName=1467d47dm55暂无昵称, createdTime=Sun Jan 19 07:34:14 CST 2025, time=2025-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2162463, encodeId=8ce221624639f, content=投稿7个月了，外审时间都半年了，催了几次回复都一样。问一下大家，是不是审稿人不回复，编辑就一直等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rRiaicFp2D5Zialtibib5bH8Xicoiaa0UkU4YtcrrAfpFuwiaAlBPjztFLu3icxdzV1zkf1wYjZRbfdCsLEUtic5XuGWY1HQ/132, createdBy=b6f92385679, createdName=superzera, createdTime=Thu Oct 12 21:40:23 CST 2023, time=2023-10-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2239073, encodeId=e6a722390e3ed, content=9月28号Under Review，11月25日还在找审稿人，整整两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Mon Nov 25 15:38:06 CST 2024, time=2024-11-25, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2238647, encodeId=67a7223864e06, content=审稿速度:6.0 经验分享：二审2个月，找了第3个审稿人，审的最初投稿版本，用前两个审稿人的问题给我拒了，去哪说理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6a8350383, createdName=ms6000001780597345, createdTime=Sat Nov 23 12:21:10 CST 2024, time=2024-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省)]

2024-11-23 ms6000001780597345 来自广西

审稿速度:6.0
经验分享：二审2个月，找了第3个审稿人，审的最初投稿版本，用前两个审稿人的问题给我拒了，去哪说理？

37 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2270503, encodeId=f8b522e0503f3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：淀粉;纤维素 经验分享：提交一周送审，两周初审结束, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b54c9485214, createdName=ms1000000879411280, createdTime=Mon Jun 23 10:09:45 CST 2025, time=2025-06-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2141072, encodeId=008d21410e2f0, content=10号投稿，当天with editor。15号变成decision，现在还在等待决定。已经快一个月了，有相同经历的朋友吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bb75418039, createdName=gyoun9, createdTime=Tue Jun 06 14:51:37 CST 2023, time=2023-06-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2248748, encodeId=160e2248e48f8, content=一审14个月，一直跟我说审稿人还缺一个，我到底要不要撤稿，耽误太久太久了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c375142848, createdName=1467d47dm55暂无昵称, createdTime=Sun Jan 19 07:34:14 CST 2025, time=2025-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2162463, encodeId=8ce221624639f, content=投稿7个月了，外审时间都半年了，催了几次回复都一样。问一下大家，是不是审稿人不回复，编辑就一直等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/rRiaicFp2D5Zialtibib5bH8Xicoiaa0UkU4YtcrrAfpFuwiaAlBPjztFLu3icxdzV1zkf1wYjZRbfdCsLEUtic5XuGWY1HQ/132, createdBy=b6f92385679, createdName=superzera, createdTime=Thu Oct 12 21:40:23 CST 2023, time=2023-10-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2239073, encodeId=e6a722390e3ed, content=9月28号Under Review，11月25日还在找审稿人，整整两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Mon Nov 25 15:38:06 CST 2024, time=2024-11-25, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2238647, encodeId=67a7223864e06, content=审稿速度:6.0 经验分享：二审2个月，找了第3个审稿人，审的最初投稿版本，用前两个审稿人的问题给我拒了，去哪说理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6a8350383, createdName=ms6000001780597345, createdTime=Sat Nov 23 12:21:10 CST 2024, time=2024-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省)]

2023-08-27 125a246am56暂无昵称来自安徽省

偏重的研究方向：蛋白;生物材料
经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？

138 5 举报

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务